299 related articles for article (PubMed ID: 10137850)
1. Investigational drug tracking: phases I-III and NDA submissions--Part II.
Grant KL
Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
[TBL] [Abstract][Full Text] [Related]
2. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
Grant KL
Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
4. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
5. Oncology's first Phase 0 trial.
Rowan K
J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
[No Abstract] [Full Text] [Related]
6. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
7. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs.
Kefalas CH; Ciociola AA
Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264
[No Abstract] [Full Text] [Related]
8. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
9. Operation of a radiopharmacy for a clinical trial.
Norenberg JP; Petry NA; Schwarz S
Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
[TBL] [Abstract][Full Text] [Related]
10. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
[TBL] [Abstract][Full Text] [Related]
11. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.
Alper K; Schwartz KA; Kolts RL; Khan A
Biol Psychiatry; 2007 Aug; 62(4):345-54. PubMed ID: 17223086
[TBL] [Abstract][Full Text] [Related]
12. Projecting future drug expenditures--1993.
Santell JP
Am J Hosp Pharm; 1993 Jan; 50(1):71-7. PubMed ID: 8427283
[TBL] [Abstract][Full Text] [Related]
13. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
[TBL] [Abstract][Full Text] [Related]
14. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
15. The investigative process for new drugs.
Nicklas RA
Ann Allergy; 1989 Dec; 63(6 Pt 2):598-600. PubMed ID: 2688499
[TBL] [Abstract][Full Text] [Related]
16. Critical assessment of international clinical development programmes for new antihypertensive drugs.
Ménard J
J Hypertens Suppl; 1993 Dec; 11(5):S39-46. PubMed ID: 8158432
[TBL] [Abstract][Full Text] [Related]
17. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
18. Exisulind Cell Pathways.
Griffiths GJ
Curr Opin Investig Drugs; 2000 Nov; 1(3):386-91. PubMed ID: 11249724
[TBL] [Abstract][Full Text] [Related]
19. Expanded access to investigational drugs for treatment use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
[TBL] [Abstract][Full Text] [Related]
20. Sources of regulatory information for pharmacists.
Goldwire MA; Rumore MM
Am J Hosp Pharm; 1993 Jun; 50(6):1175-81. PubMed ID: 8517457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
